Skip to main content

Table 1 Patients’ characteristics for analysis of LILRB4 expression on human lung macrophages

From: Upregulation of leukocyte immunoglobulin-like receptor B4 on interstitial macrophages in COPD; their possible protective role against emphysema formation

Characteristics Never-smokers
(n = 21)
Non-COPD smokers
(n = 16)
COPD
(n = 14)
P value
Age (years) 68.5 ± 8.7 67.6 ± 5.5 75.5 ± 3.7  < 0.001
Male/female 3/18 13/3 13/1  < 0.0001
Smoking (pack-years) 0 39.6 ± 29.2 48.4 ± 32.0  < 0.0001
FVC (L) 2.8 ± 0.7 3.2 ± 0.9 3.2 ± 0.5 0.017
FEV1 (L) 2.2 ± 0.6 2.6 ± 0.4 2.1 ± 0.3 0.004
FEV1/FVC (%) 83.9 ± 6.2 95.9 ± 11.0 63.5 ± 5.7  < 0.0001
FEV1 (% of predicted value) 108.5 ± 19.3 91.5 ± 8.6 82.6 ± 9.4  < 0.0001
% DLCO 97.1 ± 17.2 86.4 ± 19.5 93.1 ± 33.6 N.S
% DLCO/VA (% predicted value) 103.7 ± 16.3 93.5 ± 28.9 79.7 ± 23.4 N.S
GOLD stage (I/II) 11/3  
  1. Data are presented as mean ± standard deviation or number. FVC forced vital capacity, FEV1 forced expiratory volume in 1 s, DLCO diffusing capacity of the lung for carbon monoxide, GOLD global initiative for chronic obstructive lung disease, N.S. not significant